ReviewDrug discovery today2007
Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs).
Review in Drug discovery today, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed.
- Chemical composition and oral sub-chronic safety of Algerian propolis with in silico targeting of Keap1-Nrf2 and mitochondrial proteins.Scientific reports · 2026Article
- Sex hormones and their receptors in osteoarthritis: current research progress.Annals of joint · 2026Review
- Exploring Cutting-Edge Strategies for the Management of Triple-Negative Breast Cancer Through Drug Repurposing.Current topics in medicinal chemistry · 2026Review
- First multifaceted ADME profile of ACP-105 (CAS: 1048998-11-3): a novel non-steroidal selective androgen receptor modulator used as doping in sports-integrative in silico toxicological studies for clinical and forensic toxicology purposes.Archives of toxicology · 2025Article
- Ligandrol lowers endurance and negatively affects lipid and hormonal profile of male rats.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Unveiling the Potential of S4 on Non-small Cell Lung Cancer Cells: Impact on Proliferation, Apoptosis, Senescence, and Metabolome Profile.Anti-cancer agents in medicinal chemistry · 2025Article
- Ostarine blunts the effect of endurance training on submaximal endurance in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Illegal products containing selective androgen receptor modulators purchased online from Italy: health risks for consumers.Sexual medicine · 2024Article
- Osteoporosis treatment: current drugs and future developments.Frontiers in pharmacology · 2024Review
- Characterization of allosteric modulators that disrupt androgen receptor co-activator protein-protein interactions to alter transactivation-Drug leads for metastatic castration resistant prostate cancer.SLAS discovery : advancing life sciences R & D · 2023Article
- Androgen Receptor and Cardiovascular Disease: A Potential Risk for the Abuse of Supplements Containing Selective Androgen Receptor Modulators.Nutrients · 2023Review
- Identification and Synthesis of Selected In Vitro Generated Metabolites of the Novel Selective Androgen Receptor Modulator (SARM) 2f.Molecules (Basel, Switzerland) · 2023Article
- Androgen receptor antagonists produced by Streptomyces overcome resistance to enzalutamide.The Journal of antibiotics · 2021Article
- Differential Expression of Androgen Receptor in Type I and Type II Endometrial Carcinomas: A Clinicopathological Analysis and Correlation with Outcome.Oman medical journal · 2021Article
- Medicinal Use of Testosterone and Related Steroids Revisited.Molecules (Basel, Switzerland) · 2021Review
- Investigation of Equine In Vivo and In Vitro Derived Metabolites of the Selective Androgen Receptor Modulator (SARM) ACP-105 for Improved Doping Control.Metabolites · 2021Article
- Computational Analysis of Residue-Specific Binding Free Energies of Androgen Receptor to Ligands.Frontiers in molecular biosciences · 2021Article
- Pharmaceutical Care in Sports.Pharmacy (Basel, Switzerland) · 2020Article
- Drug Repurposing for Triple-Negative Breast Cancer.Journal of personalized medicine · 2020Review
- Selective androgen receptor modulators (SARMs) have specific impacts on the mouse uterus.The Journal of endocrinology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Selective androgen receptor modulators (SARMs) are a novel class of androgen receptor (AR) ligands that might change the future of androgen therapy dramatically. With improved pharmacokinetic characteristics and tissue-selective pharmacological activities, SARMs are expected to greatly extend the clinical applications of androgens to osteoporosis, muscle wasting, male contraception and diseases of the prostate. Mechanistic studies with currently available SARMs will help to define the contributions of differential tissue distribution, tissue-specific expression of 5alpha-reductase, ligand-specific regulation of gene expression and AR interactions with tissue-specific coactivators to their observed tissue selectivity, and lead to even greater expansion of selective anabolic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.